Related Experiment Video
Updated: Aug 13, 2026
An Improved Method for Rapid Intubation of the Trachea in Mice
Published on: February 22, 2016
Phosgene inhalation injury in mice: Modeling human pathophysiology, biomarker discovery, and therapeutic target
Sarah M Long1, Ana I Caceres2, Alan D Marcus2
1Department of Anesthesiology, Duke University School of Medicine, Durham, NC 27710, USA; Division of Laboratory Animal Resources, Duke University School of Medicine, Durham, NC 27710, USA.
Abstract:
Phosgene gas, also known as choking gas (CG; military designation), has been used in warfare and terrorism and remains a major industrial and transportation hazard. Phosgene inhalation causes severe pulmonary edema, acute lung injury, and high mortality; however, no forensic diagnostic biomarkers or mechanism-based medical countermeasures are currently available. Here, we developed a reproducible mouse model of phosgene-induced acute respiratory distress syndrome (ARDS), identified candidate biomarkers and drug targets, and evaluated pharmacological inhibition of transient receptor potential vanilloid 4 (TRPV4) as a potential countermeasure. 8-9-week-old male and female BALB/c mice were exposed to 20 ppm phosgene for 15 min using a nose-only exposure system. At 8 h post-exposure, bronchoalveolar lavage fluid (BALF), lung, and sensory ganglia were analyzed for inflammatory, vascular, functional, transcriptional, proteomic, and histopathological endpoints. Phosgene exposure increased BALF total protein and albumin, indicating alveolar-capillary barrier disruption, and induced leukocyte influx, pro-inflammatory cytokines, vascular injury and coagulation markers, impaired lung mechanics, airway hyperresponsiveness, and ARDS-like histopathology characterized by septal thickening and intra-alveolar neutrophilic/proteinaceous debris. Multiplex protein profiling identified 63 differentially expressed biomarkers that distinguished phosgene-exposed mice from air controls and captured key mechanisms of toxic inhalation injury, including inflammation, immune activation, endothelial dysfunction, vascular leakage, matrix remodeling, and impaired repair. Many of these proteins are linked to FDA-approved or investigational therapeutics, nominating actionable drug targets for medical countermeasure development. Treatment with the TRPV4 antagonist GSK2220691 attenuated phosgene-induced pulmonary injury, supporting TRPV4 inhibition as a promising mechanism-based therapeutic strategy for phosgene inhalation injury.
Insights
This study developed a mouse model for phosgene inhalation injury, identifying biomarkers and a potential treatment targeting the TRPV4 channel to mitigate lung damage.
Area of Science:
- Toxicology
- Pulmonary Medicine
- Biomarker Discovery
Background:
- Phosgene gas (CG) exposure causes severe lung injury and high mortality.
- No effective treatments or diagnostic biomarkers currently exist for phosgene inhalation injury.
- Reproducible animal models for phosgene-induced acute respiratory distress syndrome (ARDS) are limited.
Purpose of the Study:
- To establish a reproducible mouse model of phosgene inhalation injury.
- To identify forensic diagnostic biomarkers and potential therapeutic targets.
- To evaluate a mechanism-based medical countermeasure for phosgene exposure.
Main Methods:
- Mice were exposed to 20 ppm phosgene for 15 minutes.
- Collected bronchoalveolar lavage fluid (BALF) for cellular and cytokine analysis.
- Performed pulmonary function tests and analyzed lung tissue for gene/protein expression and histopathology.
- Evaluated the efficacy of a TRPV4 antagonist (GSK2220691) as a medical countermeasure.
Main Results:
- Phosgene exposure increased BALF protein, albumin, and leukocytes, indicating vascular leakage and barrier disruption.
- Elevated pro-inflammatory cytokines, vascular injury markers, and coagulation disorders were observed.
- Histopathology revealed ARDS features, including thickened alveolar septa and neutrophil accumulation.
- 63 differentially expressed protein biomarkers were identified, reflecting inflammation, endothelial dysfunction, and impaired repair.
- TRPV4 antagonism significantly reduced phosgene-induced pulmonary injury.
Conclusions:
- A reproducible mouse model for phosgene inhalation injury was successfully developed.
- Identified protein biomarkers can aid in forensic diagnosis and suggest therapeutic targets.
- TRPV4 antagonism represents a promising mechanism-based medical countermeasure for phosgene exposure.
